Geisinger

Geisinger Health Plan Policies and Procedure Manual

Policy: MP048

Section: Medical Benefit Policy

Subject: Surgical and Minimally Invasive Therapies for the Treatment of Benign Prostatic Hypertrophy

Applicable line of business:

Commercial	**x**	**Medicaid**	**x**
Medicare	**x**	**ACA**	**x**
CHIP	**x**		

I. Policy: Surgical and Minimally Invasive Therapies for the Treatment of Benign Prostatic Hypertrophy

II. Purpose/Objective:
To provide a policy of coverage regarding Surgical and Minimally Invasive Therapies for the Treatment of Benign Prostatic Hypertrophy

III. Responsibility:
A. Medical Directors
B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

Commercial

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicare

Geisinger Gold Medicare Advantage HMO, PPO, and HMO D-SNP plans are offered by Geisinger Health Plan/Geisinger Indemnity Insurance Company, health plans with a Medicare contract. Continued enrollment in Geisinger Gold depends on contract renewal. Geisinger Health Plan/Geisinger Indemnity Insurance Company are part of Geisinger, an integrated health care delivery and coverage organization.

CHIP

Geisinger Health Plan Kids (GHP Kids) is a Children's Health Insurance Program (CHIP) offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicaid

Geisinger Health Plan Family (GHP Family) is a Medical Assistance (Medicaid) insurance program offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization

V. Additional Definitions
Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
c. in accordance with current standards of good medical treatment practiced by the general medical community.
d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment
Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

INDICATIONS:
Transurethral Microwave Thermotherapy (TUMT), Transurethral Radiofrequency Thermotherapy (TUNA), Transurethral incision of the prostate (TUIP), Transurethral water vaporization of the prostate [e.g. Rezum™] (TUVP), Transurethral enucleation of the prostate (TUEP), Laser Prostatectomy (Holmium laser ablation of the prostate [HoLAP]) , Holmium laser enucleation of the prostate [HoLEP] , Holmium laser resection of the prostate [(HoLRP]), transurethral ultrasound-guided laser induced prostatectomy (TULIP), visually-guided laser ablation of the prostate (VLAP) and Water Induced Thermotherapy (WIT) are outpatient ablation treatments for symptomatic benign prostatic hypertrophy (BPH). These procedures are non-surgical alternatives to transurethral resection of the prostate (TURP). The desired outcome is to relieve urinary symptoms and improve urinary function by reducing urinary obstruction caused by BPH. A urethral probe is used to apply thermal energy to the prostate, causing damage and eventual necrosis of excess prostatic tissue. These procedures are considered to be medically necessary when the following criteria are met:

- Diagnosis of symptomatic BPH with duration of symptoms greater than 3 months
- Failed trial, intolerance, contraindication to medication therapy (alpha-blocker and/or finasteride) or medication management is felt to be ineffective.
- Recent PSA that resulted in a value of 2.5 ng/ml or less for members up to age 50; 4.0 ng/ml or less for members over age 50
- Peak urine flow rate (Qmax) less than 15 cc on a voided volume of greater than 125cc
- Post void residual (PVR) greater than 50cc or less than 350cc

Prostatic Urethral Lift (UroLift ®) is a minimally invasive implant developed to treat lower urinary tract outflow obstruction secondary to BPH in men 45 years of age or older. Permanent implants are delivered via the urethra, deployed, and implanted into each lobe of the prostate to retract the tissue away from the urethral walls to increase the opening of the urethra. This procedure is considered medically necessary when the following criteria are met:

- Diagnosis of symptomatic BPH with duration of symptoms greater than 3 months
- Prostate gland volume is less than or equal to 100 ml
- Prostate anatomy demonstrates urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH), including lateral and median lobe hyperplasia Therapeutic failure or intolerance to medical therapy (e.g. α1-adrenergic antagonists, 5α-reductase inhibitors)
- Absence of contraindications*
  *If the member has a diagnosis or history of prostate cancer and:
  - The member is not a candidate for surgical resection of the prostate but will be treated by non-surgical therapy (e.g., radiation) and has symptoms that are so severe that immediate relief is required; or
  - The member is clinically in remission as evidenced by a Prostate Specific Antigen (PSA) less than 1.0 ng/mL.

Endourethral prosthesis (e.g., Urolume® urethral stent) is considered medically necessary to treat obstruction secondary to BPH in men at least 60 years of age or older, or men under 60 years of age who are poor surgical candidates.

See also: MP093 Cystourethroscopy, with Insertion of Urethral Stent

CONTRAINDICATIONS:
Active urinary tract infection
Prostate malignancy
Hyperreflexive neurogenic bladder
Previous prostate surgery
Active cystolithiasis
Gross hematuria
Urethral stricture
Bladder neck contracture
Acute prostatitis
Prior radiation therapy to the pelvic area

EXCLUSIONS:
The Plan does **NOT** provide coverage for *transurethral balloon dilation or Drug-coated balloon catheter systems (e.g., Optilume®)* of the prostatic urethra because it is considered **unproven.** There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this treatment on health outcomes when compared to established treatments or technologies **52284**

The Plan does **NOT** provide coverage for *Transurethral ethanol ablation of the prostate (TEAP)* used in the treatment of prostatic hypertrophy because it is considered **experimental, investigational or unproven.** There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this treatment on health outcomes when compared to established treatments or technologies.

The Plan does **NOT** provide coverage for High-intensity focused ultrasound (HIFU) ablation used in the treatment of prostatic hypertrophy because it is considered **experimental, investigational or unproven**. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this treatment on health outcomes when compared to established treatments or technologies

The Plan does **NOT** provide coverage for Prostatic arterial embolization (PAE) for the treatment of BPH hypertrophy because it is considered experimental, investigational or unproven. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this treatment on health outcomes when compared to established treatments or technologies.

The Plan does **NOT** provide coverage for Transperineal laser ablation (TPLA) for the treatment of BPH hypertrophy because it is considered unproven. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this treatment on health outcomes when compared to established treatments or technologies. **0655T, 0714T, 0867T**

The Plan does **NOT** provide coverage for temporarily implanted nitinol devices (e.g., iTind) as a minimally invasive alternative to transurethral resection of the prostate (TURP) to treat symptomatic benign prostatic hyperplasia because it is considered unproven. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this treatment on health outcomes when compared to established treatments or technologies. **C9769**

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in **MP 15 - Experimental Investigational or Unproven Services or Treatment.**

Medicaid Business Segment:
Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

CODING ASSOCIATED WITH: Surgical and Minimally Invasive Therapies for the Treatment of Benign Prostatic Hypertrophy ***The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee***

provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services.

37242 Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor
52282 Cystourethroscopy, with insertion of urethral stent
52284 Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed
52441 Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant
52442 each additional permanent adjustable transprostatic implant

52450 Transurethral incision of prostate [TUIP]
52601 Transurethral electrosurgical resection of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included) [laser prostatectomy]
52630 Transurethral resection; residual or regrowth of obstructive prostatic tissue including control of postoperative bleeding, complete
52647 Non-contact laser coagulation of prostate, including control of post-operative bleeding, complete
52648 Contact laser vaporization with or without transurethral resection of prostate, including control of postoperative bleeding, complete
52649 Laser enucleation of the prostate with morcellation, including control of postoperative bleeding, complete
53850 Transurethral destruction of the prostate tissue; by microwave thermotherapy [TUMT]
53852 by radiofrequency thermotherapy [TUNA]
53854 Transurethral destruction of prostate tissue; by radiofrequency water vapor (steam) thermal therapy
53855 insertion of a temporary prostatic urethral stent, including urethral measurement
55873 Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring)
C9739 Cystourethroscopy, with insertion of transprostatic implant; 1 to 3 implants
C9740 4 or more implants
C9769 Cystourethroscopy, with insertion of temporary prostatic implant/stent with fixation/anchor and incisional struts (Nitinol, iTind device)
0421T Waterjet prostate ablation cmpl
0582T Transurethral ablation of malignant prostate tissue by high energy water vapor thermotherapy, including intraoperative imaging and needle guidance
0619T Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed
0655T Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging
0714T Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance
0867T Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 Ml
0941T Cystourethroscopy, flexible; with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization
0942T Cystourethroscopy, flexible; with removal and replacement of prostatic urethral scaffold
0943T Cystourethroscopy, flexible; with removal of prostatic urethral scaffold

LINE OF BUSINESS:
Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supercede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy For PA Medicaid Business segment, this policy applies as written.

REFERENCES:
Geisinger Technology Assessment Committee, "Microwave Thermotherapy for Benign Prostatic Hyperplasia", Jan 2002.

Geisinger Technology Assessment Committee, "Laser Therapy for Treatment of Benign Prostatic Hypertrophy", Oct. 1993.

Geisinger Technology Assessment Committee, "Transurethral Needle Ablation of the Prostate", Jan 1997, July 1999, Oct 1999.

Technology Evaluation Center, TEC Evaluation, “Transurethral Radiofrequency Needle Ablation for Benign Prostatic Hypertrophy”, Aug 1997, 12(15):1-25 and Mar 1999, 13(25):1-37.

Technology Evaluation Center, TEC Evaluation, “Laser Prostatectomy for Benign Prostatic Hypertrophy”, Mar 1994, 9(4):1-11.

Technology Evaluation Center, TEC Evaluation, “Transurethral Microwave Thermotherapy for Benign Prostatic Hyperplasia”, Nov. 1996; 11(19): 1-27.

Cioanta I, Muschter R, “Water-induced Thermotherapy for Benign Prostatic Hyperplasia”, *Techniques in Urology*, 6(4):294-299, Dec 2000.

Corcia FA, et. al., “Transurethral Hot Water Balloon Thermoablation for Benign Prostatic Hyperplasia: Patient Tolerance and Pathologic Findings”, *Urology*, 56(1):76-80, July 2000.

Muschter R, et. al.,”Transurethral Water-Induced Thermotherapy for the Treatment of Benign Prostatic Hyperplasia: A Prospective Muticenter Clinical Trial”, *Journal of Urology*, 164(5):1565-1569, Nov. 2000.

Larson TR, Blute ML, et.al., “A High Efficiency Microwave Thermoablation System for the Treatment of Benign Prostatic Hyperplasia: Results of a Randomized, Sham-Controlled, Prospective, Double-Blind, Multi-Center Clinical Trial”, *Adult Urology* 51(5):731-742, 1998.

Ramsey EW, Miller PD, Parsons K, “A Novel Transurethral Microwave Thermal Ablation System to Treat Benign Prostatic Hyperplasia: Results of a Prospective Multicenter Clinical Trial”, *Journal of Urology* 158(1):112-119, July 1997.

Djavan B, Seutz C, et.al., “Targeted Transurethral Microwave Thermotherapy Versus Alpha-Blockade in Benign Prostatic Hyperplasia: Outcomes at 18 Months”, Adult Urology 57(1):66-70, 2001.

Winifred S. Hayes. Hayes Directory (online). Laser prostatectomy for benign prostatic hyperplasia. HAYES Inc. Lansdale Pa May 22, 2006.

Balloon Dilatation of the prostatic urethra – should it have a place in the urologists armamentarium? World Journal of Urology 1991;9(1):32-35.

Wasserman NF, Reddy PK, Zhang G, Kapoor DA, Berg P. Transurethral balloon dilatation of the prostatic urethra:effectiveness in higly selected patients with prostatism. AJR AM J Roentgenol 1991 Sep;157(3):509-12.

American Urology Association. Guideline on the management of benign prostatic hyperplasia: Diagnosis and treatment. American Urology Association. 2005 Update.

Schatzl G, Madersbacher S, Djavan B, Lang T, et al. Two-year results of transurethral resection of the prostate versus four ‘less invasive’ treatment options. Eur Urol. 2000 Jun; 37(6):695-701.

Agency for Healthcare Research and Quality (AHRQ). Treatments for benign prostatic hyperplasia. Health Technology Assessments. 2004 August. No. 290-02-0019. Available at: http://www.cms.hhs.gov/mcd/viewtechassess.asp?where=search&tid=39&basket=ta:39:Treatments+for+Benign+Prostatic+Hyperplasia.

Barkin J, Giddens J, Incze P, et al. UroLift system for relief of prostate obstruction under local anesthesia. Can J Urol. 2012;19(2):6217-6222

Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: The L.I.f.T. Study. J Urol. 2013;190(6):2161-2167.

Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: Two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2012;79(1):5-11.

Cantwell AL, Bogache WK, Richardson SF, et al. Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 2014;113(4):615-622.

McNicholas TA, Woo HH, Chin PT, et al. Minimally invasive prostatic urethral lift: Surgical technique and multinational experience. Eur Urol. 2013;64(2):292-299

McVary KT, Gange SN, Shore ND, et al; L.I.F.T. Study Investigators. Treatment of LUTS secondary to BPH while preserving sexual function: Randomized controlled study of prostatic urethral lift. J Sex Med. 2014;11(1):279-287

National Institute for Health and Clinical Excellence (NICE). Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. Interventional Procedure Guidance 475. London, UK: NICE; January 2014.

Aoun F, Marcelis Q, Roumeguere T. Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: Technology update. Res Rep Urol. 2015;7:125-136.

da Silva RD, Bidikov L, Michaels W, et al. Bipolar energy in the treatment of benign prostatic hyperplasia: A current systematic review of the literature. Can J Urol. 2015;22(5 Suppl 1):30-44.
Nair SM, Pimentel MA, Gilling PJ. Evolving and investigational therapies for benign prostatic hyperplasia. Can J Urol. 2015;22(5 Suppl 1):82-87

McVary KT, Gange SN, Gittelman MC, et al. Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2016;195(5):1529-1538.

Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017a; 24(3):8802-8813

Roehrborn CG, Gange SN, Gittelman MC, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017b; 197(6):1507-1516

Pushkaran, A., Stainer, V., Muir, G., and Shergill, I. Urolift - minimally invasive surgical BPH management. Expert Review of Medical Devices, 2017;14(3), 223-228

Gratzke,C., Barber, N., Speakman, M., Berges, R., Weterauer, U., Greene, D., et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year resuls of the BPH6 prospective, multicentre, randomized study. BJU International, 2017;119 (5), 767-775.

Cunningham GR, Kadmon D. Transurethral procedures for treating benign prostatic hyperplasia. UpToDate

Bhojani N, Bidair M, Zorn KC, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 1-year results. Urology. 2019;129:1-7.

McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology Gold Journal. 2019 Jan 23

Rukstalis D, Grier D, Stroup SP, Tutrone R, deSouza E, Freedman S, David R, Kaminetsky J, Eure G. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis 2019 Sep; 22(3): 411-419.

Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, VcVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rashid P. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 217; 24(3): we8802-8813.

Eure G, Gange S, Walter P, Khan A, Chabert C, Mueller T, Cozzi P, Patel M, Freedman S, Chin P, Ochs S, Hirsh A, Trotter M, Grier D. Real-World Evidence of Prostatic Urethral Lift Confirms Pivotal Clinical Study Results: 2-Year Outcomes of a Retrospective Multicenter Study. J Endourol 2019 Jul; 33(7): 576-584

Virasoro R, DeLong JM, Mann RA, et al. A drug-coated balloon treatment for urethral stricture disease: Interim results from the ROBUST I study. Can Urol Assoc J. 2020;14(6):187-191.

Abt D, Hechelhammer L, Müllhaupt G, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: Randomised, open label, non-inferiority trial. BMJ. 2018;361:k2338.

Bagla S, Martin CP, van Breda A, et al. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2014;25(1):47-52.

Cizman Z, Isaacson A, Burke C, et al. Short- to midterm safety and efficacy of prostatic artery embolization: A systematic review. J Vasc Interv Radiol. 2016;27(10):1487-1493.

Bhatia S, Sinha VK, Harward S, et al. Prostate artery embolization in patients with prostate volumes of 80 ml or more: A single-institution retrospective experience of 93 patients. J Vasc Interv Radiol. 2018a;29(10):1392-1398.

Bhatia S, Sinha VK, Kava BR, et al. Efficacy of prostatic artery embolization for catheter-dependent patients with large prostate sizes and high comorbidity scores. J Vasc Interv Radiol. 2018b;29(1):78-84.

Malling B, Roder MA, Brasso K, et al. Prostate artery embolisation for benign prostatic hyperplasia: A systematic review and meta-analysis. Eur Radiol. 2019;29(1):287-298.

Insausti I, de Ocariz AS, Galbete A, et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2020;31(6):882-890.

Lerner LB, McVary, KT, Barry MJ et al: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part I, initial work-up and medical management. J Urol 2021; 206: 806

Centers for Medicare & Medicaid Services. Novitas L38712 Transurethral Waterjet Ablation of the Prostate. A58243 Billing and Coding: Transurethral Waterjet Ablation of the Prostate

Cai HJ, Fang JH, Kong FL, et al. Ultrasound-guided transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: A new minimally invasive interventional therapy. Acta Radiol. 2022;63(4):553-558.

Gilling P, Barber N, Bidair M, et al. Five-year outcomes for Aquablation compared to TURP: Results from a double-blind randomized trial in men with LUTS due to BPH. Can J Urol. 2022;29(1)

Taratkin M, Shpikina A, Morozov A, et al. Enucleation vs. vaporization of benign prostatic hyperplasia: A head-to-head comparison of the various outcomes and complications. A systematic review and meta-analysis. Minerva Urol Nephrol. 2022;74(5):559-569

Bates AS, Ayers J, Kostakopoulos N, et al. A systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with standard management options: limitations of the available evidence and recommendations for clinical practice and further research. Eur Urol Oncol. 2021; S2588-9311(20)30216-9.

Chao B, Lepor H. 5-year outcomes following focal laser ablation of prostate cancer. Urology. 2021; 155:124-129.

Mehralivand S, George AK, Hoang AN, et al. MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up. Diagn Interv Radiol. 2021; 27(3):394-400

Nicoletti R, Alberti A, Castellani D et al. Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs). Prostate Cancer Prostatic Dis. 2023. Epub ahead of print.

Kadner G, Valerio M, Giannakis I, et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol. Dec 2020; 38(12): 3235-3244.

Amparore D, Fiori C, Valerio M, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. Jun 2021; 24(2): 349-357.

Amparore D, De Cillis S, Schulman C, et al. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results. Minerva Urol Nephrol. Dec 2023; 75(6): 743-751.

De Nunzio C, Cantiello F, Fiori C, et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. World J Urol. Jun 2021; 39(6): 2037-2042.

Porpiglia F, Fiori C, Amparore D, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int. Jun 2019; 123(6): 1061-1069.

Franco JV, Jung JH, Imamura M, et al. Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis. Cochrane Database Syst Rev. Jul 15 2021; 7(7): CD013656.

Chughtai B, Elterman D, Shore N, et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology. Jul 2021; 153: 270-276

Elterman D, Alshak MN, Diaz SM, et al. An evaluation of sexual function in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia in men treated with the temporarily implanted nitinol device. J Endourol. 2023 ;37(1):74-79.

Virasoro R, DeLong JM, Mann RA, et al. A drug-coated balloon treatment for urethral stricture disease: Interim results from the ROBUST I study. Can Urol Assoc J. 2020;14(6):187-191.

This policy will be revised as necessary and reviewed no less than annually**.**

Devised: 06/02

Revised: 6/03 (definition); 6/04; 6/06 (references); 7/07, 7/08 (added exclusion), 7/09(added exclusion), 6/12, 9/12, 6/16 (added covered therapy), 6/17(clarified covered services), 6/19 (add covered therapies, reformat criteria); 6/20 (revise UroLift criteria); 6/21 (add cross reference and exclusion); 6/22 (revised coverage criteria); 6/23 (added procedures); 6/24 (add exclusions: TPLA. iTind, Optilume)

Reviewed: 6/05, 6/10, 6/11, 9/13, 9/14, 9/15, 6/18, 6/25

CMS UM Oversight Committee Approval: 12/23, 7/24, 8/25